Epizyme Inc. (EPZM)

10.82
0.02 0.18
NASDAQ : Health Technology
Prev Close 10.84
Open 10.80
Day Low/High 10.71 / 10.84
52 Wk Low/High 5.14 / 16.59
Volume 57.69K
Avg Volume 632.10K
Exchange NASDAQ
Shares Outstanding 91.04M
Market Cap 941.32M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Epizyme To Participate In Upcoming September Conferences

Epizyme To Participate In Upcoming September Conferences

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following September investor conferences: Citi...

Epizyme Reports Business Progress And Second Quarter 2019 Results

Epizyme Reports Business Progress And Second Quarter 2019 Results

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline highlights and reported second quarter 2019 financial results.

Epizyme To Present At The Wedbush PacGrow 2019 Healthcare Conference

Epizyme To Present At The Wedbush PacGrow 2019 Healthcare Conference

Epizyme, Inc. (Nasdaq:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Wedbush PacGrow 2019 Healthcare Conference on...

Epizyme Announces FDA Filing Acceptance Of New Drug Application And Priority Review For Tazemetostat For The Treatment Of Epithelioid Sarcoma

Epizyme Announces FDA Filing Acceptance Of New Drug Application And Priority Review For Tazemetostat For The Treatment Of Epithelioid Sarcoma

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.

Epizyme Strengthens Leadership Team With Appointment Of Paolo Tombesi As Chief Financial Officer

Epizyme Strengthens Leadership Team With Appointment Of Paolo Tombesi As Chief Financial Officer

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019.

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat In Patients With Relapsed Or Refractory Follicular Lymphoma

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat In Patients With Relapsed Or Refractory Follicular Lymphoma

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed...

Epizyme Announces Conference Call To Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

Epizyme Announces Conference Call To Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma At 2019 ASCO Annual Meeting

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma At 2019 ASCO Annual Meeting

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported updated data on tazemetostat from the epithelioid sarcoma cohort of its ongoing Phase 2 study in patients with molecularly defined...

Epizyme Submits New Drug Application To The U.S. FDA For Tazemetostat For The Treatment Of Patients With Epithelioid Sarcoma

Epizyme Submits New Drug Application To The U.S. FDA For Tazemetostat For The Treatment Of Patients With Epithelioid Sarcoma

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.

Epizyme To Present At Jefferies 2019 Healthcare Conference

Epizyme To Present At Jefferies 2019 Healthcare Conference

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5,...

Epizyme Announces New Tazemetostat Clinical Data To Be Presented In Oral Sessions At Multiple Upcoming Medical Meetings

Epizyme Announces New Tazemetostat Clinical Data To Be Presented In Oral Sessions At Multiple Upcoming Medical Meetings

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company's ongoing Phase 2 clinical trials of...

Epizyme Provides Business Update And Reports First Quarter 2019 Financial Results

Epizyme Provides Business Update And Reports First Quarter 2019 Financial Results

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2019 financial results.

First Week Of EPZM November 15th Options Trading

First Week Of EPZM November 15th Options Trading

Investors in Epizyme Inc. saw new options become available this week, for the November 15th expiration.

Epizyme Announces Closing Of Concurrent Public Offerings And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme Announces Closing Of Concurrent Public Offerings And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series...

Epizyme Announces Pricing Of Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme Announces Pricing Of Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme, Inc. (Nasdaq:EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting...

Epizyme Announces Proposed Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme Announces Proposed Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten...

Epizyme Announces Presentations At Upcoming March Investor Conferences

Epizyme Announces Presentations At Upcoming March Investor Conferences

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences: Cowen 39 th Annual Health Care Conference on Tuesday,...

Epizyme Provides Business Update And Reports Fourth Quarter And Full Year 2018 Financial Results

Epizyme Provides Business Update And Reports Fourth Quarter And Full Year 2018 Financial Results

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2018 financial results.

Epizyme Announces Date Of Fourth Quarter And Full Year 2018 Results And Upcoming Presentation At The 8th Annual SVB Leerink Global Health Care Conference

Epizyme Announces Date Of Fourth Quarter And Full Year 2018 Results And Upcoming Presentation At The 8th Annual SVB Leerink Global Health Care Conference

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018...

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

First Week Of August 16th Options Trading For Epizyme (EPZM)

First Week Of August 16th Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options begin trading this week, for the August 16th expiration.

Epizyme Announces Registration Path For Tazemetostat For Follicular Lymphoma And Provides Pipeline Updates And 2019 Guidance

Epizyme Announces Registration Path For Tazemetostat For Follicular Lymphoma And Provides Pipeline Updates And 2019 Guidance

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat...

Epizyme Earns $8 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For First-in-Class PRMT1 Inhibitor

Epizyme Earns $8 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For First-in-Class PRMT1 Inhibitor

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced it has earned an $8 million milestone payment from GlaxoSmithKline (GSK).

Epizyme Is Now Oversold (EPZM)

Epizyme Is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Announces Conference Call To Discuss Corporate Updates

Epizyme Announces Conference Call To Discuss Corporate Updates

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.

Epizyme Reports Third Quarter 2018 Financial Results And Tazemetostat Progress

Epizyme Reports Third Quarter 2018 Financial Results And Tazemetostat Progress

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the third quarter of 2018 and provided updates on its tazemetostat clinical development program.

Oversold Conditions For Epizyme (EPZM)

Oversold Conditions For Epizyme (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO

Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a...

TheStreet Quant Rating: D (Sell)